Evidence map›Paper›PMID 42460398›Full record

ArticleOpen forum infectious diseases2026

Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.

Jonathan Huggins, Julia A Messina, Jennifer Saullo, Jiayi Xie, Amy Zhang, Ishan Paranjpe, Rong Lu, Megan Walsh, Michael Mohnasky, Joseph Stromberg and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jonathan HugginsDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0001-9529-036X
Julia A MessinaDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0001-6411-198X
Jennifer SaulloDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Jiayi XieDivision of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0001-8977-6654
Amy ZhangDepartment of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, California, USA.
Ishan ParanjpeDivision of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, USA.
Rong LuDepartment of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, California, USA.
Megan WalshDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Michael MohnaskyDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-2536-0200
Joseph StrombergDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Felicia CaoDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Natalie GroverDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-1346-3157
Manish SahaDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Alicia DarwinDepartment of Medicine, Stanford University Hospital, Stanford, California, USA.
Nancy TorresDepartment of Medicine, Stanford University Hospital, Stanford, California, USA.
Patrick TamDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Daniel SchrumDivision of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.
Erin EberweinDivision of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.
Erin KennedyDivision of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.
Christopher R KelseyDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Taewoong ChoiDivision of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.
Matthew McKinneyDivision of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.
Yubin KangDivision of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.
Melody SmithDivision of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-2702-0381
Tessa M AndermannDivision of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-0844-7400

Funding

Precision characterization of antimicrobial resistance gene dynamics in bloodstream infection risk after hematopoietic stem cell transplantationK23AI163365 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANDERMANN, TESSA · 2021 to 2025
$1.0M
NIAID NIH HHS K23 AI163365
6 · The paper itself

Abstract

Background: Our understanding of the epidemiology of and risk factors for postchimeric antigen receptor T-cell therapy (CART) infections is largely based on data from single-center studies with small sample sizes. Methods: This is a multicenter, cohort study of adult patients treated with CD19 CART between 1 January 2018 and 31 August 2021. The epidemiology of infectious complications occurring within the first year after CART is described. A Fine-Gray subdistribution hazard model was built to identify risk factors for infection. Logistic regression was used to explore risk factors for early (≤90 days post-CART) versus late (>90 days post-CART) and bacterial versus viral infection. Results: One hundred and thirty-one infections occurred in 97 of 311 patients (31.2%) within 1 year of CART. By infection type, the cumulative incidence of infection was 19.0% (viral), 20.9% (bacterial), and 2.3% (fungal). The majority of infections were mild or moderate in severity (86%). Conclusions: Infectious complications occur in close to a third of patients post-CART but are generally mild in severity. Though we were not able to identify independent predictors of post-CART infection, a description of their clinical characteristics and epidemiology will help to optimize management of these common complications.

Indexed as

bacterialCD19chimeric antigen Receptor T-cellfungalimmunocompromised hostlymphomaviral

Identifiers

PMID42460398
PMCPMC13371758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.